UPDATE: Citi Upgrades Regeneron To Buy, Raises Target To $420 As Firm Notes 'We think between Libtayo data next year and continuous Dupi growth, investors will find it easy to stay invested through near-term Eylea competition'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/07/2019 18:45